Hudson Bay Capital Management LP Trims Holdings in Intellia Therapeutics, Inc. $NTLA

Hudson Bay Capital Management LP lowered its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 50.5% during the third quarter, Holdings Channel.com reports. The institutional investor owned 230,000 shares of the company’s stock after selling 235,000 shares during the period. Hudson Bay Capital Management LP’s holdings in Intellia Therapeutics were worth $3,972,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of NTLA. Schroder Investment Management Group raised its position in Intellia Therapeutics by 1,593.4% during the 2nd quarter. Schroder Investment Management Group now owns 406,425 shares of the company’s stock worth $3,812,000 after buying an additional 382,425 shares during the last quarter. Farallon Capital Management LLC purchased a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at $10,486,000. Marex Group plc purchased a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at $5,849,000. JPMorgan Chase & Co. increased its stake in shares of Intellia Therapeutics by 73.0% in the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock worth $8,822,000 after acquiring an additional 396,858 shares during the period. Finally, AXQ Capital LP acquired a new stake in shares of Intellia Therapeutics in the second quarter worth $285,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $12.84 on Friday. The company has a market capitalization of $1.52 billion, a PE ratio of -3.35 and a beta of 2.10. The company’s fifty day moving average price is $13.06 and its 200 day moving average price is $13.29. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.16. The company had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The firm’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.27) earnings per share. On average, equities analysts expect that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on NTLA. restated a “buy” rating on shares of Intellia Therapeutics in a research report on Tuesday, March 3rd. William Blair raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday, March 2nd. Royal Bank Of Canada lifted their price objective on Intellia Therapeutics from $9.00 to $15.00 and gave the company a “sector perform” rating in a research note on Tuesday, March 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, January 22nd. Finally, Citizens Jmp raised their target price on Intellia Therapeutics from $21.00 to $28.00 and gave the stock a “market outperform” rating in a report on Tuesday, March 3rd. Ten analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $19.59.

Insider Activity

In related news, EVP James Basta sold 10,397 shares of Intellia Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the completion of the transaction, the executive vice president owned 101,528 shares in the company, valued at $935,072.88. The trade was a 9.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the completion of the transaction, the executive vice president directly owned 98,533 shares of the company’s stock, valued at $907,488.93. The trade was a 7.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 53,051 shares of company stock worth $488,600 in the last ninety days. Company insiders own 3.10% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.